MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
MAXCYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.30+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $138.87M
- P/E (TTM)
- –
- Dividend yield
- –
MAXCYTE, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product sales | $18.69M | $21.09M | $18.60M | $27.73M | $20.79M | $14.85M | $12.92M | 56.6% | -11.4% |
| Licenses | $12.37M | $16.41M | – | – | – | – | – | 37.5% | -24.6% |
| Assay and other service revenue | $1.97M | – | – | – | – | – | – | 6.0% | – |
| Other | – | $1.13M | $897.00K | $1.02M | $784.60K | $601.30K | $339.40K | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $21.08M | $25.77M | $32.42M | – | – | – | – | 63.8% | -18.2% |
| Outside the United States | $11.95M | $12.86M | $8.87M | – | – | – | – | 36.2% | -7.1% |
From the segment and revenue-disaggregation notes of Maxcyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.